This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Covid-19 Vaccinations Promise to Ramp Up
by Mark Vickery
Guidance for the end of 2020 was to have 20 million Americans with the first half of the two-injection immunization treatment; as of now, only around 9 million Americans have received the first dose.
Moderna (MRNA) Stock Up on Vaccine Pipeline Expansion Plan
by Zacks Equity Research
Moderna (MRNA) plans to initiate clinical studies on new candidates as potential vaccine for seasonal flu, HIV and the Nipah virus.
What Will Be the Main Economic Drivers in 2021?
by John Blank
With 2020 in the rear-view mirror, we are leaving behind us a plethora of events that affected and shaped our society and economy.
CureVac (CVAC) Up on Deal With Bayer for COVID-19 Vaccine
by Zacks Equity Research
CureVac (CVAC) gains on a collaboration agreement with Bayer (BAYRY) for further development and supply of its COVID-19 vaccine candidate, CVnCoV.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and AstraZeneca
Moderna (MRNA) COVID-19 Vaccine Gets Authorization in Europe
by Zacks Equity Research
Moderna (MRNA) gets conditional use authorization for coronavirus vaccine, mRNA-1273, for use in adults in EU member states.
FDA Opposes Dilution of COVID-19 Vaccine Doses: Here's Why
by Indrajit Bandyopadhyay
The FDA is against any changes to the approved dosing regimens for Pfizer (PFE)/BioNTech (BNTX) and Moderna's (MRNA) coronavirus vaccines as demanded by some experts.
Moderna (MRNA) Raises COVID-19 Vaccine Production Target
by Zacks Equity Research
Moderna (MRNA) raises lower end of its global manufacturing target for its coronavirus vaccine by 20% for 2021. The company still aims to deliver up to one billion doses in the year.
5 Momentum Stocks Bargain Hunters Would Love Chasing
by Nilanjan Choudhury
To tap the market's rally, it will be prudent to invest in momentum stocks that are still cheap. Our choices are Winnebago Industries (WGO), Fiat Chrysler (FCAU), FedEx (FDX), Williams-Sonoma (WSM) and Lennar (LEN).
AstraZeneca (AZN) COVID-19 Vaccine Gets Authorization in UK
by Zacks Equity Research
AstraZeneca's (AZN) vaccine for coronavirus receives emergency use approval in the United Kingdom, the first for it anywhere in the world.
Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study Results
by Zacks Equity Research
Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.
5 Factors Indicating That Oil is Poised for a Run-Up in 2021
by Nilanjan Choudhury
As a proof of the improving energy environment, refining biggies like Marathon Petroleum (MPC) and Phillips 66 (PSX) experienced sequential increase in utilization during the third quarter.
Novavax (NVAX) Initiates Phase III Study on COVID-19 Vaccine
by Zacks Equity Research
Novavax (NVAX) initiates phase III study on its coronavirus vaccine, NVX-CoV2373, in the United States and Mexico.
Pfizer (PFE) Lorbrena First-Line sNDA Gets FDA Priority Review
by Zacks Equity Research
Pfizer's (PFE) label expansion application for Lorbrena as first-line treatment for metastatic lung cancer gets priority review from the FDA.
5 Sector ETFs That Beat the Market in 2020
by Sweta Killa
With historic twists and turns, 2020 has turned out to be a banner year.
5 Stocks That Could Directly Gain From Pfizer's Vaccine Success
by Zacks Equity Research
As vaccine rollout picks up in the United States, companies directly involved in the distribution process stand to benefit, making it wise to keep an eye on names like FedEx (FDX) and Linde (LIN)
Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to U.S.
by Zacks Equity Research
Pfizer (PFE)/BioNTech(BNTX) won a deal for 100 million more doses of its COVID-19 vaccine in the United States.
6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19
by Zacks Equity Research
We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.
Evergreen Tree of ETFs to Lighten Your Christmas
by Sweta Killa
The Christmas tree of top-ranked ETFs to brighten 2021 is now ready for investors. May it spread cheer!
Stock Market News for Dec 24, 2020
by Zacks Equity Research
Benchmarks closed mixed on Wednesday after investors¿¿¿ sentiment were overshadowed by President Trump¿¿¿s opposition on fresh stimulus packages passed by the Congress.
5 Bank Stocks Set to Rebound With Vaccine-Driven Economic Recovery
by Radhika Saraogi
Improving lending scenarios and restoration of normal activities in 2021, with the help of coronavirus vaccines rollout, will likely help banks like JPMorgan (JPM), Bank of Hawaii (BOH), Bank OZK (OZK), UMB Financial (UMBF) and Synovus (SNV) witness a rebound.
3 Airlines Stocks to Gain as the Economy Looks to Fully Reopen
by Zacks Equity Research
Rollout of the vaccine along with an expected fiscal stimulus is sure to boost the airlines industry, making it prudent to watch out for names like Mesa Air Group (MESA) and Spirit Airlines (SAVE).
Small-Caps at Record Highs Ahead of Christmas
by Mark Vickery
The small-cap Russell 2000 index has hit another closing record high today -- the 13th time this has occurred this year.
Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) continue to take centerstage in the biotech sector.
BioCryst (BCRX) Provides Updates on Galidesivir, Shares Fall
by Zacks Equity Research
BioCryst (BCRX) will discontinue the study on its pipeline candidate, galidesivir, for treating patients with the novel coronavirus disease (COVID-19).